Answers are grounded in this paper and cite their sources.
The type 1 IGF receptor (IGF-IR) is activated by two ligands, IGF-1 and IGF-2, and by insulin at supraphysiological concentrations. It plays a significant role in the growth of normal and abnormal cells, and antibodies against the IGF-IR are now in clinical trials. Targeting of the IGF-IR in cancer cells (by antibodies or other means) can be improved by the appropriate selection of responsive tumors. This review focuses on the optimization of IGF-IR targeting in human cancer.
No takes yet. Share an insight, caveat, or question.
Renato Baserga (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: